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Abstract 
Purpose: To evaluate the in vitro effects of combining kanamycin and metronidazole against resistant 
bacteria. 
Methods: The influence of combining kanamycin and metronidazole against Gram-positive and Gram-
negative bacteria was assessed by agar diffusion, checkerboard and time-kill assays.  
Results: The test isolates were highly resistant, with minimum inhibitory concentration (MIC) ranging 
between 15.63 and >250 µg/ml for kanamycin, and 15.63 and 125 µg/ml for metronidazole. The 
antibacterial combinations resulted in drastic decrease in MIC with increased antibacterial activity that 
indicated synergistic interaction against all the bacteria except Acinetobacter calcaoceuticus UP, 
Enterobacter cloacae ATCC 13047 and Shigella flexneri KZN. Fractional inhibitory concentration index 
(FICI) showed synergy ranging from 0.31 to 0.50, additive interaction with FICI ranging from 0.53 to 
1.25 and absence of antagonistic interaction. Escherichia coli ATCC 25922, Enterococcus faecalis 
ATCC 29212, Bacillus cereus ATCC 10702, Enterobacter cloacae ATCC 13047, Klebsiella pneumoniae 
ATCC 10031, Acinetobacter calcoaceuticus UP and Micrococcus luteus were totally eliminated by the 
antibacterial combinations within 24 h of incubation. The lack of antagonism between these antibacterial 
agents in checkerboard and time-kill assays suggest that kanamycin may be effective in both 
monotherapy and combination therapy. 
Conclusion: The study indicates the potential beneficial value of combining kanamycin and 
metronidazole in the treatment of microbial infections in clinical settings.  
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Infectious diseases are a significant cause of 
morbidity and mortality, accounting for 
approximately 50 % of all deaths in tropical 
countries [1]. Due to indiscriminate use of 
antibacterial agents in infectious diseases, 
multidrug resistance in bacteria has become a 
great challenge to human health [2]. With the 
increasing prevalence of multi-drug resistant 
bacteria, appearances of strains with reduced 
susceptibility to antibiotics and their inexorable 
invasion of hospitals and communities, there are 
increases in health care costs [3], many 
untreatable bacterial infections and the need to 
search for new infection-fighting strategies and 
novel antibacterial agents [4].  
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The use of antimicrobial combinations to achieve 
synergistic activities against targeted 
microorganisms is a potential strategy for 
overcoming bacterial resistance [5]. 
Theoretically, it is aimed at broadening 
antimicrobial empirical coverage, improving 
efficacy against isolates with a minimum 
inhibitory concentration (MIC) at or approaching 
the breakpoint for susceptibility as well as 
preventing the further emergence of resistant 
organisms [6]. While preventing the emergence 
of reduced susceptibility, it achieves bactericidal 
synergy and provides activity against stationary-
phase organisms and organisms growing in 
biofilm. The use of drug combinations is an 
excellent strategy to avoid drug resistance since 
different drug target sites are attacked 
simultaneously. Although previous studies 
indicated interactions between other 
aminoglycosides or nitroimidazole 
(metronidazole) and other antibacterial agents 
[7,8], combining kanamycin and metronidazole 
against bacteria of clinical importance has not 
been reported. This study, therefore, aimed at 
assessing the effect of combining kanamycin and 
metronidazole, having different mechanisms of 




Bacterial strain  
 
The bacteria used in this study include 
Acinetobacter calcoaceuticus UP, Bacillus 
cereus ATCC 10702, Escherichia coli ATCC 
25922, Enterococcus faecalis ATCC 29212, 
Enterobacter cloacae ATCC 13047, Klebsiella 
pneumoniae ATCC 10031, Shigella flexneri KZN, 
Micrococcus luteus, Enterococcus faecalis KZN 
and Staphylococcus aureus OK2b. They were 
obtained from the Department of Biochemistry 
and Microbiology, University of Fort Hare, Alice, 
South Africa. The antibacterial assays were 
carried out using Mueller Hinton II Agar (Biolab) 
and broth.  
 
Antibiotics used in this study 
 
Stock solutions of Kanamycin (Duchefa) and 
Metronidazole (Duchefa) were prepared 
according to the CLSI (Clinical Laboratory 
Standardization Institute) method or 
manufacturer’s recommendations [9].  
 
Antibiotic susceptibility testing  
 
Each of the bacterial isolates was standardized 
using colony suspension method [10]. Each 
strain's suspension was matched with 0.5 
McFarland standards to give a resultant 
concentration of 1 × 106 cfu/ml. The antibiotic 
susceptibility testing was determined by 
swabbing the Mueller-Hinton agar (MHA) (Oxoids 
U.K) plates with the resultant saline suspension 
of each bacterial strain. Wells were then bored 
into the agar medium with heat sterilized 6 mm 
cork borer. The wells were filled with 100 µl of 
different concentrations (62.5, 125 and 250 
µg/ml) of each of the antibiotics without allowing 
spillage of the solutions onto the agar surfaces. 
To determine the combinatorial effect of the 
antibiotics, different solutions containing 
combined concentrations (62.5, 125 and 250 
µg/ml) of kanamycin and metronidazole were 
used. The plates were allowed to stand for at 
least 30 min before being incubated at 37 °C for 
24 h. The determinations were done in duplicate. 
After 24 h of incubation, the plates were 
examined for inhibition zones. The diameter of 
the inhibition zones produced by the respective 
antibiotic alone and their combinations were 
measured and interpreted using the CLSI zone 
diameter interpretative standards [11].  
 
Determination of minimum inhibitory 
concentration (MIC)  
 
The minimum inhibitory concentrations (MICs) for 
the two antibiotics were determined in duplicate 
by the macrobroth dilution method in Mueller 
Hinton broth. To determine the MICs of each 
antibiotic, different concentrations of each of the 
antibiotics (0.0019 - 500) μg/ml were prepared by 
serial dilution in Mueller Hinton broth. To 
determine their combined effects, combinations 
of different concentrations were used in the 
determination of the MICs of each of the 
antibiotics were used. The tubes were inoculated 
with 100 µl of each of the adjusted bacterial 
strains before incubating at 37 oC for 24 h. Blank 
Mueller Hinton broth was used as negative 
control. The MICs were determined in duplicates. 
The MIC was defined as the lowest 
concentrations that showed no growth in the 




The interactions between the two antibiotics were 
determined using the checkerboard as previously 
described [12]. The range of drug concentration 
used in this assay encompassed the MIC for 
each antibiotic used in the analysis. The 
fractional inhibitory concentration (FIC) was 
derived from the lowest concentrations of the two 
antibiotics in combination permitting no visible 
growth of the test organisms in the Mueller 
Hinton broth after incubation for 24 h at 37 oC. 
FIC indices were calculated using the formula, 
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FIC index = (MIC of kanamycin in 
combination/MIC of kanamycin alone) + (MIC of 
metronidazole in combination/MIC of 
metronidazole alone). In this study, synergy was 
defined as ∑FIC ≤ 0.5, additivity as 0.5 < ∑FIC ≤ 
1, indifference as 1 < ∑FIC ≤ 4. Concentrations 
within the FIC panel were such that the MIC of 
each antibiotic was in the middle of the range of 
concentrations tested but lower than the MICs of 
the respective antibiotics. 
 
Determination of rate of kill 
 
The rates of kill by the combined antibiotics were 
carried out using a modified plating technique of 
Eliopoulos and Moellering [13]. The combined 
antibiotics incorporated into 10 ml of Mueller 
Hinton broth in McCartney bottles at ½ MIC and 
MIC were inoculated with approximately 1010 
cfu/ml further verified by total viable count.  
Inoculated Mueller Hinton broth without 
combined antibiotics and uninoculated Mueller 
Hinton broth incorporated with the combined 
antibiotics at the test concentrations were 
included as controls. The tubes were incubated 
at 37 oC on an orbital shaker at 120 rpm. A 100 
µl aliquot was removed from the culture medium 
at 0, 24 and 48 h for the determination of cfu/ml 
by plating out 25 µl of each of the dilutions in 
duplicates. After incubating at 37 oC for 24 h, 
emergent bacterial colonies were counted, cfu/ml 
calculated and compared with the counts 





Data, analyzed by SPSS V.16 (Statistical 
Program for Social Sciences, SPSS Corporation, 
Chicago, IL), were expressed as means ± 
standard deviations (SD) of duplicate 
determinations. One way analysis of variance 
(ANOVA) and the Duncan’s New Multiple-range 
test were used to determine the differences 





Acinetobacter calcoaceuticus UP and 
Enterococcus faecalis KZN were highly resistant 
to kanamycin while other isolates exhibited 
concentration dependent susceptibility to its 
varied concentrations. Enterococcus faecalis 
KZN was susceptible to the different 
concentrations of metronidazole while 
Enterococcus faecalis ATCC 29212, Klebsiella 
pneumoniae ATCC 10031 and Acinetobacter 
calcoaceuticus UP were slightly inhibited at the 
highest concentration. Other isolates were not 
affected by the different concentrations used.  
 
On combining different concentrations of the two 
antibiotics, concentration dependent significant 
synergistic interactions were observed. The 
resultant zones of inhibition from the antibacterial 
combinations were wider than those obtained 
from the antibacterial activities of each of the 
antibiotics (Table 1). Though the bacteria 
showed varied resistance to both antibiotics, 
resistant colonies were not isolated within the 
zones of inhibition and fuzzy zones were not 
found around the edges of the zones of 
inhibition. 
 
From the macrobroth assay, the test isolates 
were highly resistant to the two antibiotics by 
exhibiting minimum inhibitory concentrations 
(MICs) ranging between 15.625 and >250 µg/ml 
for kanamycin and 15.625 – 125 µg/ml for 
metronidazole. On combining the two antibiotics 
against these bacteria, the MICs of both 
antibiotics were drastically reduced in the range 
between ½ MIC and 1/8 MIC with a simultaneous 
increase in the antibacterial activity of the 
combined antibiotics (Table 2).  The results of 
both assays were complementary. The 
significant reduction in the MICs and the 
observed increase in the inhibition zones from 
the combined antibiotics showed that the 
resultant effect of combining these two antibiotics 
was synergy.  
 
In the checkerboard assay, antibacterial 
combinations showed synergistic interaction 
against most of the bacteria except 
Acinetobacter calcoaceuticus UP, Enterobacter 
claoacae ATCC 13047 and Shigella flexneri 
KZN. While the fractional inhibitory concentration 
indices (FICIs) showed synergy ranging from 
0.3125 – 0.5, an additive interaction was 
indicated with FICI ranging between 0.5313 and 
1.25 and no antagonism was recorded from the 
antibacterial combinations. 
 
The time-kill assay results presented as changes 
in the log10 cfu/ml of viable colonies showed that 
the antibacterial combinations exhibited a 
significant bactericidal activity. The bactericidal 
activity was defined as being equal to 3 log10 
cfu/ml or greater reduction in the viable colony 
count relative to the initial inoculum [14]. 
Escherichia coli ATCC 25922, Enterococcus 
faecalis ATCC 29212, Bacillus cereus ATCC 
10702, Enterobacter cloacae ATCC 13047 and 
Micrococcus luteus were completely annihilated 
by the combination of kanamycin and  
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Reduction in bacterial counts (Log10CFU/ml) for the combined 
antibiotics 
MIC50% MIC 
0 (h) 24 (h) 48 (h) 0 (h) 24 (h) 48 (h) 
 
Escherichia coli ATCC 25922 7.18 0 0 6.90 0 0 
Enterococcus faecalis ATCC 29212 8.90 0 0 8.91 0 0 
Bacillus cereus ATCC 10702 7.62 0 0 7.26 0 0 
Enterobacter cloacae ATCC 13047 12.15 0 0 12.38 0 0 
Klebsiella pneumoniae ATCC 10031 11.51 5.78 5.97 11.61 0 0 
Acinetobacter calcaoceuticus UP 12.70 3.45 3.94 12.81 0 0 
Shigella flexneri KZN 12.43 3.92 4.32 12.51 3.86 3.96 
Micrococcus luteus 11.93 0 0 11.99 0 0 
Enterococcus faecalis KZN 10.42 4.11 4.54 11.15 3.90 4.28 
Staphylococcus aureus OK2b 9.38 5.13 5.27 9.66 3.94 4.08 
 
metronidazole at ½ MICs. These bacteria along 
with Klebsiella pneumoniae ATCC 10031 and 
Acinetobacter calcoaceuticus UP were totally 
killed by the antibacterial combination at the 
MICs within 24 h of incubation. Shigella flexneri 
KZN, Enterococcus faecalis KZN and 
Staphylococcus aureus OK2b were not totally 
inhibited at the combined MICs despite the 
degree of synergism observed because each of 
the isolates exhibited a very high level of 
resistance to either or both antibiotics.  
 
Average log reduction in viable cell count in time-
kill assay for Klebsiella pneumoniae ATCC 
10031, Acinetobacter calcoaceuticus UP, 
Shigella flexneri KZN, Enterococcus faecalis 
KZN and Staphylococcus aureus OK2b not 
totally eliminated, however, ranged between 
3.4472 Log10 to 5.7782 Log10 cfu/ml after 24 h of 
incubation with the combined antibiotics at the ½ 
MIC and MIC values (Table 3). A post-antibiotic 
treatment bioassay done after 48 h showed that 
all isolates not totally inhibited within 24 h 




Due to the frequent development of resistance 
during monotherapy treatment of infected 
patients, multiple combinations of antibacterial 
agents are being proposed [15]. These were to 
effectively treat mixed and severe infections, 
enhance antibacterial activity, reduce the time 
needed for long-term antimicrobial therapy and 
prevent the emergence of resistant 
microorganisms [16] because drug combinations 
are characterized by an increased activity and 
tolerability compared to that of monotherapy and 
those used to increase the killing of single-drug 




In this study, the checkerboard method 
demonstrated synergy between kanamycin and 
metronidazole for the majority of the strains while 
antagonism was not observed. The combined 
antibiotics indicated ability to improve the 
bactericidal effects of each other on both Gram-
negative and Gram-positive bacteria. This is in 
agreement with previous reports on interaction 
between aminoglycosides and other antibacterial 
agents [17]. Their combination in chemotherapy 
could decrease resistance development, broaden 
antibacterial spectrum and encourage synergistic 
antibacterial activity [18]. 
 
As determined by Eliopoulos and Moellering [13], 
antibiotic combinations that reduced the original 
inocula by ≥ 2 log10 cfu/ml were considered 
synergy while antagonism is a < 2 log10 change 
in cfu/ml when compared with the activity of the 
individual antibiotic after 24 h incubation period. 
The time-kill assay confirmed the synergy 
between kanamycin and metronidazole as 
indicated by the checkerboard assay. This 
synergy that resulted in enhanced antibacterial 
effects from antibiotics having different 
mechanisms of action could have resulted from 
the formation of a complex compound with 
enhanced antibacterial activity. Since kanamycin 
prevents bacteria from synthesizing proteins by 
binding to 16S rRNA of 30S subunit and 
metronidazole is reduced to cytotoxic polar 
compounds able to cause DNA strand breakage, 
DNA helix and nucleic acid destabilization in 
bacteria [19], the synergy of the antibacterial 
combination could be a means of achieving 
effective therapy at a reduced cost with a drastic 
reduction or loss of vestibular and auditory 
toxicity often associated with the 
aminoglycosides While the lack of antagonism 
between the antibiotics suggested that 
kanamycin or metronidazole may be effective in 
monotherapy and combination therapy, this 
synergy will reduce the dose of each drug in the  
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Table 1: Mean zone of inhibition (± 1.0 mm) produced by each antibiotic and their combinations at various concentrations 
 
ZONE OF INHIBITION (± 1.0 mm) 
Test bacterium 
Kanamycin alone (µg/ml) Metronidazole (µg/ml)  Kan-Met combinations (µg/ml) 
250 125 62.5 250 125 62.5 250/250 125/125 62.5/62.5 
 
Escherichia coli ATCC 25922 25±1.00c 20±0.58d 18±0.58f 0± 0.00g 0± 0.00g 0± 0.00g 29± 1.00 a 26± 1.00b 20± 0.58 d 
Enterococcus faecalis ATCC 29212 26±0.58b 24±0.58c 21±0.58d 16± 0.58e 0± 0.00f 0± 0.00f 27± 1.53 a 24± 1.53c 21± 0.58 d 
Bacillus cereus ATCC 10702 27±0.58b 24±0.58d 22±0.58f 0± 0.00g 0± 0.00g 0± 0.00g 29± 0.58 a 25± 0.58c 23± 0.58 e 
Enterobacter cloacae ATCC 13047 22±1.00b 20±0.58c 19±0.58d 0± 0.00f 0± 0.00f 0± 0.00f 25± 0.00 a 22 ± 0.58b 20± 0.58 c 
Klebsiella pneumoniae ATCC 10031 28±0.58b 25±0.58d 21±0.58f 13± 0.58g 0± 0.00h 0± 0.00h 29 ± 0.58 a 27 ± 0.58c 22± 0.58 e 
Acinetobacter calcaoceuticus UP 0±0.00e 0±0.00e 0±0.00e 14± 0.58d 0± 0.00e 0± 0.00e 26± 0.58 a 24± 0.58b 20± 0.58 c 
Shigella flexneri KZN 28±0.58a 25±0.58c 23±0.58d 0± 0.00f 0± 0.00f 0± 0.00f 28± 1.53 a 26± 0.58b 22± 0.58 e 
Micrococcus luteus 24±0.58c 21 ±0.58d 20± 0.58e 0± 0.00f 0± 0.00f 0± 0.00f 28± 1.00 a 25 ± 0.58b 21± 0.58 d 
Enterococcus faecalis KZN 0±0.00g 0±0.00g 0±0.00g 20± 0.58d 19 ± 1.00e 14 ± 0.58f 31± 0.58 a 28± 1.53b 23± 0.58 c 
Staphylococcus aureus OK2b 28±0.58a 24±0.58c 22± 0.58d 0± 0.00f 0± 0.00f 0± 0.00 f 26± 0.58 b 24± 0.58 c 20± 0.58 e 
Note: The mean inhibition zones with different superscript along the same row are significantly different (p < 0.05) 
 
Table 2: Fractional inhibitory concentration values for the antibiotics alone and their combinations against resistant bacterial isolates 
 
 Minimum inhibitory concentration (µg/ml) Fractional inhibitory concentration index 
Test bacterium Kanamycin  Metronidazole  KAN-MET  FICI Kan FICI Met FICI Remarks  
Escherichia coli ATCC 25922 125 31.25 15.63/7.81 0.13 0.25 0.38 Synergistic 
Enterococcus faecalis ATCC 29212 125 31.25 15.63/7.81 0.13 0.25 0.38 Synergistic 
Bacillus cereus ATCC 10702 125 31.25 7.81/7.81 0.06 0.25 0.31 Synergistic 
Enterobacter cloacae ATCC 13047 62.5 31.25 15.63/15.63 0.25 0.5 0.75 Additive 
Klebsiella pneumoniae ATCC 10031 31.25 31.25 7.81/7.81 0.25 0.25 0.5 Synergistic 
Acinetobacter calcaoceuticus UP > 250 15.63 7.81/7.81 0.03 0.5 0.53 Additive 
Shigella flexneri KZN 15.63 62.25 15.63/15.63 1.0 0.25 1.25 Indifference 
Micrococcus luteus 250 31.25 15.63/7.81 0.06 0.25 0.31 Synergistic 
Enterococcus faecalis KZN > 250 62.5 15.63/15.63 0.06 0.25 0.31 Synergistic 











Olajuyigbe & Afolayan 
Trop J Pharm Res, May 2015; 14(5): 842  
 
combination and prevent the development of 
bacterial resistance [20]. 
 
Although bactericidal drugs prevent the 
emergence of resistant mutants by killing the 
microorganism [21] while synergy and 
bactericidal therapy could be achieved as long as 
the organism does not exhibit high-level 
resistance to aminoglycoside [22], it is evident, 
from this study, the highly resistant bacteria with 
MIC ranging between 15.625 and >250 µg/ml for 
kanamycin were killed by its combination with 
metronidazole to which the MICs were between 
15.625 and 125 µg/mL for the different isolates.  
 
The regrowth of Shigella flexneri KZN, 
Enterococcus faecalis KZN and Staphylococcus 
aureus OK2b can be attributed to the preferential 
killing of the susceptible subpopulations allowing 
the selective increase of the resistant 
subpopulation of each of these resistant strains 
after 48 h incubation. Further treatment or 
subsequent doses of the antibacterial 





Combining existing antimicrobial agents such as 
kanamycin and metronidazole can improve 
delivery of safe and cost effective patient care in 
an era where research into discovery of new 
agents is limited and expensive. In clinical 
settings, this study emphasizes the potential 
beneficial value of combining kanamycin and 
metronidazole for treating seriously ill patients 
with infections caused by the pathogens tested, 
especially in the absence of other therapeutic 
options. Future studies in in vivo infection models 
would provide a better understanding of the 
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